This site is intended for health professionals only

Published on 3 August 2013

Share this story:
Twitter
LinkedIn

FDA expands age indication for Menveo®

Novartis announced today that the US Food and Drug Administration (FDA) approved Menveo® (Meningococcal Group A, C, W-135 and Y conjugate vaccine) for the prevention of meningococcal disease caused by four strains of the bacterium Neisseria meningitidis (N. meningitidis) in infants and toddlers from two months of age.[1]

Novartis announced today that the US Food and Drug Administration (FDA) approved Menveo® (Meningococcal Group A, C, W-135 and Y conjugate vaccine) for the prevention of meningococcal disease caused by four strains of the bacterium Neisseria meningitidis (N. meningitidis) in infants and toddlers from two months of age.[1]
With this expanded indication, paediatricians in the US can now offer a single vaccine for the protection of infants, children and adolescents against four of the five most common serogroups that cause meningococcal disease.[1,5]
“Each year, more children in the US die or are left with permanent disability from meningococcal disease than from two other diseases combined that we routinely vaccinate infants against – rotavirus and varicella,” said Dr. Steve Black, Center for Global Health, University of Cincinnati Children’s Hospital. “With the expanded indication for this MCV4 vaccine, we now have the opportunity to help protect our infants against four strains of meningococcal disease earlier, when they are most vulnerable.”
Infants younger than seven months old are the most vulnerable age group to meningococcal disease in the US. In their first year of life, infants are more than seven times more likely to contract the disease than 14 to 24 year olds.[4] Of the infants who contract the disease, more than 10% will die from it and of those who do survive, approximately one in every five will suffer permanent, devastating side effects, including amputations, hearing loss, paralysis and brain damage.[3,6]
“Despite recommendations for routine immunisation of adolescents, college students living in dormitories and certain infants in the US, meningococcal disease continues to kill and maim,” said Andrin Oswald, Head of Novartis Vaccines and Diagnostics. “With this approval for the expanded use of Menveo, we hope that health authorities will deploy this vaccine to further reduce the burden of this devastating disease in the US.”
This FDA approval was based on data from three randomised multicentre studies involving more than 8,700 infants, conducted in Australia, Canada, Latin America, Taiwan and the US. The studies demonstrated that Menveo generated a robust protective immune response and was generally well tolerated when administered with other routine paediatric vaccines.[1]
About Menveo
Menveo is a quadrivalent conjugate vaccine for use to protect against invasive disease caused by four groups of the bacterium Neisseria meningitidis (A, C, Y and W-135).[1] As of July 2013, Menveo is registered in more than 50 countries for active immunisation to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.[1] Studies are ongoing in infants, toddlers, adolescents and adults.
Menveo has been available for use in adolescents and adults (11 to 55 years of age) since February 2010 and in children (2 to 10 years of age) since January 2011.[1,7]
For more information about Menveo, visit www.menveo.com.
References
  1. Menveo Prescribing Information. Revised August 13, 2013. To be confirmed.
  2. Centers for Disease Control and Prevention. Vaccine Information Statements (VIS). Meningococcal VIS. October 2011 Update. Available at: http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening.html. Accessed July 2013.
  3. Poland, GA. Prevention of Meningococcal Disease: Current Use of Polysaccharide and Conjugate Vaccines. Clinical Infectious Diseases 2010:50 (Suppl 2):S45-S53.
  4. Cohn, A. et al. Changes in Neisseria meningitides Disease Epidemiology in the United States, 1998-2007: Implications for Prevention of Meningococcal Disease. Clinical Infectious Diseases 2010:50.
  5. Centers for Disease Control and Prevention. Meningococcal Disease: Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book: Course Textbook). 12 Edition, 2nd Printing. May 2012 update. Available at: http://www.cdc.gov/vaccines/pubs/pinkbook/mening.html. Accessed: July 2013.
  6. World Health Organization. Meningococcal meningitis. Fact sheet #141. November  2012. Available at: http://www.who.int/mediacentre/factsheets/fs141/en/. Accessed July 2013.
  7. Novartis Press Release.  FDA requests additional data on Novartis quadrivalent meningococcal conjugate vaccine, Menveo®, for expanded use in infants and toddlers. Available at: http://www.novartis.com/newsroom/media-releases/en/2012/1584870.shtml. Accessed July 2013.


Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn